FDA Signals a Renewed Posture Toward Rare Disease

A recent meeting between acting FDA Commissioner Kyle Diamantas and senior executives from fifteen rare disease nonprofits offers a useful read on where the agency may be heading on one of the most closely watched areas in drug development.

The 90-minute session, attended by Diamantas, acting CDER Director Mike Davis, and acting CBER Director Karim Mikhail, signaled a renewed focus on rare disease engagement and a stated commitment to preventing political interference in the work of career review staff. Attendees described the tone as constructive, with FDA leadership emphasizing regular dialogue with the rare disease community, more frequent advisory committee meetings, and efforts to rebuild review capacity following the 2025 staffing reductions.

For the rare disease community, the signal matters. The past eighteen months have been marked by frustration on multiple fronts: a slate of rejections of rare disease therapies, congressional scrutiny on both sides of the aisle, and a public debate about whether the agency’s approach to small-population indications has appropriately balanced rigor against the realities of disease prevalence and unmet need. At a February Senate Aging Committee hearing, advocates testified that 23 new rare disease drugs had been rejected since the start of 2025.

What changes from here remains to be seen. The new leadership has been explicit that it will not discuss specific applications, and the policy direction remains in development. But the willingness to convene the rare disease community, to listen to advocates’ concerns, and to publicly commit to protecting the integrity of scientific review represents a meaningful shift in posture.

For companies developing therapies in rare and orphan indications, the practical implications are worth watching. A few themes from the meeting are likely to shape the policy environment ahead:

• Improved infrastructure for evidence in small populations. Advocates emphasized the need for tools and methodologies that can support treatment effect determination in small, heterogeneous patient populations. This is a long-standing challenge in rare disease drug development.
• Greater openness to novel trial designs. Biomarker development, alternative trial structures, and clinical trial efficiency were specifically raised. For sponsors, this aligns with a broader industry trend toward designs that recognize the constraints of rare disease research.
• Restoration of review capacity. Both center directors indicated efforts to recruit additional review staff, including returning former FDA personnel. Reviewer bandwidth has been a recurring concern across the industry.

None of this is a guarantee. Regulatory posture can shift, leadership is acting, and the substance of individual reviews continues to depend on the science and the data submitted. But for an industry segment where regulatory engagement is often the rate-limiting step, the willingness of FDA leadership to publicly recommit to rare disease as a priority is a development worth noting.

The rare disease community has long argued that small patient populations and life-altering disease burden warrant approaches that are scientifically rigorous and pragmatically calibrated. The FDA’s renewed engagement suggests that argument may be finding a more receptive audience.